Onaga Chotaro, Tamori Shoma, Matsuoka Izumi, Ozaki Ayaka, Motomura Hitomi, Nagashima Yuka, Sato Tsugumichi, Sato Keiko, Tahata Kouji, Xiong Yuyun, Nakano Yoshio, Mano Yasunari, Miyazaki Satoru, Sasaki Kazunori, Ohno Shigeo, Akimoto Kazunori
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Cancer Diagn Progn. 2022 Jul 3;2(4):429-442. doi: 10.21873/cdp.10126. eCollection 2022 Jul-Aug.
BACKGROUND/AIM: Radiotherapy is one of the main treatments for estrogen receptor-positive (ER+) breast cancer. However, in some ER+ breast cancer cases, radiotherapy is insufficient to inhibit progression and there is a lack of markers to predict radiotherapy insensitivity. Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been proposed to be a viable prognostic marker for luminal A and B types of ER+ breast cancer. The present study examined the possibility of SLC20A1 as a novel biomarker for the prediction of radiotherapy efficiency.
The Molecular Taxonomy of Breast Cancer International Consortium dataset was downloaded from cBioportal and the prognosis of patients with high SLC20A1 expression (SLC20A1 ) was compared with that of patients with low SLC20A1 expression, without or with radiotherapy and tumor stages I, II, and III, using the Kaplan-Meier method and multivariate Cox regression analyses of disease-specific and relapse-free survival.
Patients in the SLC20A1 group with radiotherapy showed poor clinical outcomes in both luminal A and luminal B breast cancers. Furthermore, in luminal A breast cancer at tumor stage I, patients in the SLC20A1 group with radiotherapy also showed poor clinical outcomes. Therefore, these results suggest that radiotherapy is insufficient for patients in the SLC20A1 group for both luminal A and B types, and especially for the luminal A type at tumor stage I.
SLC20A1 can be used as a prognostic marker for the prediction of the efficacy of radiotherapy for luminal A and luminal B breast cancers.
背景/目的：放射治疗是雌激素受体阳性（ER+）乳腺癌的主要治疗方法之一。然而，在一些ER+乳腺癌病例中，放射治疗不足以抑制肿瘤进展，且缺乏预测放射治疗不敏感性的标志物。溶质载体家族20成员1（SLC20A1）是一种钠/无机磷酸盐共转运体，已被提议作为腔面A型和B型ER+乳腺癌的一种可行的预后标志物。本研究探讨了SLC20A1作为预测放射治疗疗效的新型生物标志物的可能性。
从cBioportal下载国际乳腺癌分子分类数据集，采用Kaplan-Meier法和疾病特异性及无复发生存的多变量Cox回归分析，比较高SLC20A1表达（SLC20A1 ）患者与低SLC20A1表达患者在有无放射治疗以及肿瘤I、II和III期情况下的预后。
接受放射治疗的SLC20A1 组患者在腔面A型和腔面B型乳腺癌中均显示出较差的临床结局。此外，在肿瘤I期的腔面A型乳腺癌中，接受放射治疗的SLC20A1 组患者也显示出较差的临床结局。因此，这些结果表明，放射治疗对SLC20A1 组的腔面A型和B型患者均不足，尤其是对肿瘤I期的腔面A型患者。
SLC20A1可作为预测腔面A型和腔面B型乳腺癌放射治疗疗效的预后标志物。
